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Glucortoticoid Testing in Transgenic Mice 
Using a transgenic line of mice containing 5.2 kb of the human 
elastin gene promoter, Ledo and her colleagues (p. 632) demon-
strate that subcutaneous injections of glucocorticosteroids upregu-
late the human elastin promoter. Topical glucocorticosteroids are 
the treatment of choice for a variety of inflammatory skin diseases. 
However, they often produce dermal atrophy, which is usually 
attributed to loss of collagen, the main extracellular matrix compo-
nent of the dermis. Elastin is another fibrillar component of the 
dermis and gives the skin its elasticity. The human gene for elastin 
contains three putative glucocorticoid response elements within its 
promoter region; and thus, through the binding of ligands, is also 
responsive to glucocorticosteroids. Ledo et al report here the devel-
opment of a transgenic line of mice that can be used as an itl vivo 
model to study effects of glucocorticoids on regulation of the 
human elastin gene. They linked the human elastin promoter to a 
reporter gene for a bacterial enzyme, chloramphenicol acetyl trans-
ferase (CAT). Because this enzyme is not present in human or 
mouse tissues, the direct assay of CAT activity reflects the activity of 
the human elastin promoter in these transgenic mice. After subcuta-
neous injection of triamcinolone acetonide or dexamethasone, the 
authors found a marked enhancement of CAT activity. Thus the 
glucocorticosteroids upregulated the human elastin promoter. 
These transgenic mice may provide a new way of testing topical 
corticosteroids ill vivo. 
The Anchoring Fibril in Epidermal-Dermal Adherence 
Lapiere et al (p. 637) report that a small domain of the anchoring 
fibril uniquely binds fibronectin. Anchoring fibrils consist of colla-
gen type VII, a basement membrane specific collagen that exi.sts 
only beneath stratified squamous epithelia. How this collagen 111-
teracts with other connective tissue components to mediate epider-
mal-dermal adherence is unclear. Nevertheless, findings in several 
bullous skin diseases where the adherence of the epidermis to the 
dermis is perturbed suggest that the anchoring fibril plays an impor-
tant role. For example, in hereditary dystrophic epidermolysis bul-
losa (DEB) and acquired autoimmune epidermolysis bullosa (EBA), 
anchoring fibrils are sparse or absent, and when they are present, 
they are abnormally small. Likewise, anchoring fibrils are small and 
sparse within the first year after transplantation of cultured auto-
graft keratinocyte sheets to adult burn victims. This is the time 
when the healing transplanted skin areas demonstrate fragility and 
often form spontaneous blisters. In addition, when autoantibodies 
~o type VII collagen are injected into mice, the skin shows histolog-
Ical eVidence of epidermal-dermal separation. Type VII collagen has 
a large central. helical domain flanked by two non-collagenous 
glo.bular domams called NCl and NC2. The large NCl is on the 
ammo end of the central helix, while the smaller NC2 is on the 
carboxyl end. Lapiere et al show that neither NCl nor NC2 nor 
most of the helical region has an affinity for fibronectin. However, 
they do. find a sm~lI h~lical subdomain at the most carboxyl aspect of 
the heh:c where It Joms NC2 that binds fibronectin. Such unique 
lI1teractlons demonstrate the precision by which connective tissue 
components interact. Because Lapiere and colleagues have previ-
ously shown that EBA autoantibodies exclusively bind to the NCl 
domain, it is unlikely that the mechanism for EBA blister formation 
involves the fibronectin - type VII collagen bond. 
Anti-Inflammatory Agents Reduce Ultraviolet B (UVB) -Induced Erythema and Pigmentation 
Using a video image technique, Takiwaki et al (p. 642) find a linear 
relationship between the degree of UVB-induced erythema and 
subsequent pigmentation, and that both are reduced in a parallel 
manner by topical application of anti-inflammatory agents. UVB-
induced inflammation is usually followed by hyperpigmentation in 
persons with moderately pigmented skin, such as Asians. Takiwaki 
et al report here how the relationship between the degrees of in-
duced erythema and the resulting pigmentation changes when in-
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flammation is suppressed by anti-inflammatory agents. They are 
particularly interested in determining whether the resulting mela-
nogenesis in the pigmentation process following U~B ~xposure is 
influenced directly by the UVB exposure or by the initial Inflam-
matory response. With a videomicroscope interfaced with a com-
puter, they measure the changes in hemoglobin and melanin pro-
duced in the backs of Japanese volunteers after UVB exposure and 
after UVB plus indomethacin or corticosteroids. They find a linear 
relationship; that is, more UVB exposure produced more erythema 
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and more pigmentation, and addition of antiinflammatory agents 
decreased both the erythema and pigmentation in parallel. In addi-
tion, they note that dark skin is likely to produce melanin more 
efficiently than fair skin after the same UVB exposure, which pro-
duces the same inflammatory response. These findings suggest that 
chemical mediators, such as prostaglandins or possibly cytokines 
released in the inflammatory process, play an important role in the 
post-inflammatory pigmentation. 
Keratinocyte Inhibition by Heparin Is Independent of Its Anticoagulant Properties 
In this issue, Pillai et at (p. 647) report that proliferation of kerat-
inocytes in culture is inhibited by whole heparin and by heparin 
fragments that lack anticoagulant properties. In addition to antico-
agulant effects, heparin and heparin sulfate can regulate the prolif-
eration of various cell types. In keratinocytes, such growth-inhibi-
tory effects result from an interaction of heparin with autocrine 
growth factors produced by the keratinocytes, a property that may 
help explain the anecdotal reports of beneficial effects of systemic 
heparin therapy in psoriatic patients. However, because of its anti-
coagulant effects, the potential use of heparin is limited. Pillai et al 
compare the growth-inhibitory effects of whole heparin, two hepa-
rin analogues that have no anticoagulant properties, and five hepa-
rin fragments of varying oligosaccharide lengths (ranging from two 
to ten) . They find that heparin 's growth-inhibitory effects are inde-
pendent of its anticoagulant effects, and that the minimum chain 
length required is a decasaccharide unit. In addition, they determine 
that heparin's inhibition of keratinocyte proliferation does not in-
duce terminal differentiation as measured by cornified cell envelope 
formation. Finally, they show that heparin stimulates protein secre-
tion by the keratinocytes without altering protein synthesis. These 
findings suggest that heparin and its analogues may stimulate the 
release of growth inhibitory cytokines from the keratinocytes. 
Thus, non-anticoagulant heparin analogues may represent an im-
proved alternative for the treatment of hyperproliferative skin dis-
eases, such as psoriasis. 
Basal Keratinocytes Modulate Their Own Response to a Growth Factor 
In this issue, Wraight et at (p. 627) report that HaCaT cells, which 
exhibit characteristics of basal keratinocytes in culture, modulate 
their own response to insulin-like growth factor-I (IGF-I) . Kerati-
nocyte growth and the maturation of the epidermis is highly depen-
dent on a complex array of growth factors, some originating in the 
circulation, others in the dermis or epidermis. IGF-I is produced by 
dermal fibroblasts and is one of the most potent stimulators of kerat-
inocyte growth. In most tissues, the actions of IGF-I, including its 
targeting to receptors, are modulated by locally synthesized IGF 
binding proteins (IGFBPs) . Although basal keratinocytes have a 
high concentration of IGF-I receptors, they do not produce IGF-I 
themselves. Wraight and his colleagues have demonstrated that the 
HaCaT cells in culture produce one of the major species ofIGFBPs, 
which influences IGF-I responsiveness of the cells. The authors 
identify the IGFBP as IGFBP-3, a major seum IGFBP. In the cul-
ture system, the secreted IGFPB-3 inhibits the HaCaT cell's sensi-
tivity to IGF-1. This suggests that in intact skin, the response of basal 
keratinocytes to dermally-produced IGF-I is likely to be influenced 
by locally-synthesized IGFBP-3. This finding provides a better un-
derstanding of the role of IGFBPs in the IGF-I response of basal 
cells in normal and aberrant epidermal proliferation. 
